Mark E. Dudley

Medicine · Health Sciences

67h-index46.3kcitations209works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(165), Immunotherapy and Immune Responses(135), Virus-based gene therapy research(57), Immune Cell Function and Interaction(41), Cancer Immunotherapy and Biomarkers(40)

Publications208 total

Accelerating progress in immune cell therapy for solid tumours
Nature Reviews Drug Discovery·2025· 1 cited
Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes
Frontiers in Immunology·2023· 11 citedOpen Access
426 Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) drives distinct cytokine-mediated proliferation responses in CD4+ and CD8+ T cells
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
423 Single cell RNA sequencing reveals functionally validated signatures of cytotoxicity in anti-FRα CoStimulatory Antigen Receptor (CoStAR<sup>TM</sup>) activated CD4+ T cells
Regular and Young Investigator Award Abstracts·2023Open Access
Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Data from Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
2023Open Access
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Figure Legend from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
2023Open Access
Data from Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
2023Open Access
Supplemental figure 4 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Figure 1 from Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans
2023Open Access
Supplemental figure 5 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Table 1 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
2023Open Access
Data from Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans
2023Open Access
Data Supplement from Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
2023Open Access
Supplementary Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2023Open Access
Data from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
Supplementary Figure 4 from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
2023Open Access
Supplementary Figure 3 from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
2023Open Access
Supplemental figure 1 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Steven A. Rosenberg(47), John R. Wunderlich(22), Paul F. Robbins(21), Richard M. Sherry(20), Nicholas P. Restifo(20), Marybeth S. Hughes(16), Udai S. Kammula(15), James C. Yang(15), James Chih‐Hsin Yang(13), Donald E. White(10), Carolyn M. Laurençot(10), Richard A. Morgan(9), Steven A. Feldman(9), Yong F. Li(9), Giao Q. Phan(8), Kathleen E. Morton(7), Suzanne L. Topalian(6), Mona El‐Gamil(6), Mark Raffeld(5), Zhili Zheng(5)